MoonLake Immunotherapeutics
MLTX
134 hedge funds and large institutions have $270M invested in MoonLake Immunotherapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 45 closing their positions.
130% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $14.4M
3% more funds holding
Funds holding: 130 → 134 (+4)
9% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 45
20% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 41
33.32% less ownership
Funds ownership: 92.59% → 59.27% (-33%)
83% less funds holding in top 10
Funds holding in top 10: 6 → 1 (-5)
90% less capital invested
Capital invested by funds: $2.77B → $270M (-$2.5B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$78.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$66.5M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$50.3M |
| 4 |
Two Sigma Investments
New York
|
+$23.7M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$22.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$339M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$261M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$112M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$93.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$84.7M |
MLTX Hedge Fund Activity: Q3 2025 in Review
134 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2025, worth a combined $270M — down 90% from $2.77B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new MLTX positions and 45 closed out — a net gain of 4 holders — while 33 added to existing stakes and 41 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $78.2M. The largest seller was Cormorant Asset Management, cutting an estimated $339M.
- 134 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2025, up from 130 in Q2 2025.
- Funds reported $270M of MoonLake Immunotherapeutics stock for Q3 2025, down 90% quarter-over-quarter.
- 49 funds opened new MoonLake Immunotherapeutics positions in Q3 2025 and 45 closed out, a net change of +4 holders.
- The largest MoonLake Immunotherapeutics buyer in Q3 2025 was Adage Capital Partners, an estimated $78.2M added.
- The largest MoonLake Immunotherapeutics seller in Q3 2025 was Cormorant Asset Management, an estimated $339M sold.
Based on aggregated 13F filings for Q3 2025.